Eli Lilly’s Oral Obesity Drug Leads To Over 12% Weight Loss In Late-Stage Study
Synopsis
The investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies such as Lilly’s Mounjaro at 72 weeks, the company said.
Eli Lilly and Company (LLY) on Thursday said that its investigational oral weight-loss drug lowered weight by an average of 12.4% in a late-stage study at its highest dose.
The once-daily oral pill called Orforglipron showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies such as Lilly’s Mounjaro at 72 weeks, the company said.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.